GALD.SW

Galderma Group N

Beauty '26: Cosmetics & Skincare Beauty '26: Mass Market Beauty '26: Medical Aesthetics Beauty '26: Skincare GLP-1 Long '24: Improved Looks

Loading…

Overview

Galderma is a Swiss skincare and dermatology company that makes three types of products: injectables like Dysport, Restylane, and Sculptra used by dermatologist

Galderma is a Swiss skincare and dermatology company that makes three types of products: injectables like Dysport, Restylane, and Sculptra used by dermatologists and med-spas to smooth wrinkles and restore volume; skincare brands like Cetaphil and Alastin sold in stores and online; and prescription medicines like Nemluvio for chronic skin conditions. Injectables make up ~49% of sales, skincare ~32%, and therapeutics ~19%. Major retail partners like Amazon, Walmart, CVS, and large dermatology clinics drive much of its sales.

Bull / Bear Details

Galderma remains a high-quality, pure-play dermatology leader with accelerating biologic (Nemluvio) uptake, premium injectable launches (Relfydess, Sculptra), a

Thesis

Galderma remains a high-quality, pure-play dermatology leader with accelerating biologic (Nemluvio) uptake, premium injectable launches (Relfydess, Sculptra), and resilient skincare cash flows. Near-term volatility stems from U.S. filler softness and tariff headwinds, but GLP-1–driven aesthetics demand and broad international growth provide multi-year upside.

Bull case

Nemluvio ramping faster than expected with >70% commercial coverage and expanding to new indications (systemic sclerosis, chronic pruritus).
Relfydess rollout gaining traction globally, boosting neuromodulator market share and ASP mix.
GLP-1 weight-loss trend creating structural lift in demand for fillers and biostimulators; Galderma well positioned to capture “Ozempic face.”

Bear case

Aggressive U.S. filler promotions and price pressure could persist longer than expected, weighing on margins.
Nemluvio profitability still years out; heavy marketing and field-force investment may delay earnings leverage.
Tariffs and FX could pressure near-term margins despite underlying volume strength.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Tariff & margin update	U.S. tariffs and pricing pressures could hit profitability and valuation	Management commentary on tariff hit and margin guidance	Buy: tariff impact <1% of sales, margin target maintained. Sell: tariff effect >2–3% of sales or margin guidance lowered below ~22%.	Earnings or earnings-preview releases	Import duty news articles (U.S./Switzerland)	Import/export dataset for cosmetics/aesthetics
U.S. neuromodulator new product rollout (Relfydess)	New neuromodulator launch is a key driver of share gain vs incumbents	Number of markets launched, reorder rate in early markets	Buy: reorder rate >70% in early markets, >10 new markets this quarter. Sell: reorder rate <50% or launch delays announced.	Investor call, conference slides	Job postings for “Relfydess trainer”	Injectable product usage monitoring service
GLP-1 “aesthetics tailwind” evidence	The narrative of GLP-1 users needing aesthetic treatment is a strong structural growth driver	Clinic/med-spa survey data; internal commentary; media studies	Buy: published study shows significant incremental spend by GLP-1 users, or company cites >20% incremental fill rate. Sell: no incremental effect found or commentary turns negative.	Industry press, company presentations	Google Trends for “Ozempic face filler”	Med-spa billing data for GLP-1 patients
U.S. fillers & biostimulators revenue growth rate	Aesthetics is ~50% of revenue; filler softness & pricing pressure are key risk	Q3 trading update growth % for fillers & biostims	Buy: growth >10% in fillers/biostims (cc). Sell: growth <0% or negative margin impact	Q3 sales-update press release (expected ~10/22/2025) MarketScreener+1	Med-spa footfall or Instagram geo-tag count for “Sculptra”	Med-spa treatment tracking datasets
Weekly new-patient starts (NBRx) for Nemluvio in PN & AD	Nemluvio is the biologic growth engine—how fast scripts ramp = valuation re-rate potential	Weekly NBRx share data, commercial coverage update	Buy: NBRx share >35% PN or >10% AD within 12 weeks. Sell: NBRx share stagnates <25% PN or <5% AD	Company's weekly script data (if disclosed); investor slides	Google Trends for “nemolizumab start” or Reddit discussion count	Specialty pharmacy script tracking firms

Key Reported Metrics3 rows

Metric	Why It Matters	Last Period
Core EBITDA margin	Reflects ability to fund launches while maintaining profitability; shows resilience against pricing, tariffs, and marketing intensity.	22.7% (flat YoY; underlying margin ~28.9% ex-Nemluvio launch impact)
Injectable Aesthetics revenue growth	Core of the business (~50% of total revenue). Investors are watching whether new launches (Relfydess, Restylane Shape, Sculptra China) offset softness in U.S. fillers amid promotions.	'+9.8% YoY(Neuromodulators +14.7%, Fillers & Biostimulators +3.9%)
Therapeutic Dermatology (Nemluvio sales growth)	Nemluvio (nemolizumab) is Galderma's first biologic and a potential blockbuster; continued rapid ramp and market share in PN/AD are key to proving biologics can be a durable growth leg.	'+26.9% YoY for the Therapeutic Dermatology segment (Nemluvio sales: US $131 M)

Key Questions

Can Nemluvio sustain its rapid launch trajectory in both prurigo nodularis and atopic dermatitis while maintaining >70% payer coverage and moving toward breakev

Can Nemluvio sustain its rapid launch trajectory in both prurigo nodularis and atopic dermatitis while maintaining >70% payer coverage and moving toward breakeven?

Question 2: Will Relfydess and Sculptra growth offset ongoing softness and promotions in U.S. fillers, stabilizing injectable aesthetics margins?
Question 3: Is the “GLP-1 aesthetic tailwind” translating into measurable procedure and product demand, or is it still a narrative ahead of data?

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	IS CHANGE	Price Reaction
2025-07-24	Galderma posted strong H1 2025 results with 12% YoY sales growth, led by neuromodulators, Sculptra, and new biologic Nemluvio. Guidance was raised, margins steady, and cash generation solid. U.S. filler softness and tariffs tempered enthusiasm, but GLP-1-linked demand, Relfydess rollout, and Nemluvio uptake support long-term growth. Stock reaction mixed as optimism met with near-term pricing and phasing concerns.	Earnings Transcript	Mixed			+8.05% (vs SPY: +7.62%)